Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

Three monoclonal antibodies—aducanumab, lecanemab, and donanemab—that target
amyloid-β (Aβ) deposits in the brain slow cognitive and functional decline in early …

Article purpose The clinical approach to Alzheimer's disease (AD) is challenging, particularly
in high-functioning individuals. Accurate diagnosis is crucial, especially given the significant …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Alzheimer's disease is the most common cause of dementia worldwide, with the prevalence
continuing to grow in part because of the aging world population. This neurodegenerative …

Alzheimer's disease (AD) is characterized by brain protein aggregates of amyloid-β (Aβ) and
phosphorylated tau (pTau) that become plaques and tangles, and dystrophic neurites …

Highlights•Lack of success of most anti-amyloid trials in symptomatic AD is attributable in
part to the pathology being too advanced.•Progress in quantifying tau and Aβ in plasma …

Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The
presence of extracellular β-amyloid deposition as neuritic plaques and intracellular …